Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2025

Genmab — Marts 2025

Planlagt Fastgjort Låst Flyttet Genmab
961 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #834

    Bemærkelsværdigt at de ikke gjorde indsigelser med profounds patentansøgning

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #835

      Jeg ville som ledelse også sagsøge Gmab for at dække over mit $10Bn køb som nu ser mindre godt ud. Rart at kunne skyde skylden på tyveri 😄

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #836

        Abbvie køber Immunogen 30. november 2023 https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field på SITC 3. november offentliggør Profound data fra Rina-S som de nok burde have været opmærksom på https://www.biospace.com/profoundbio-presents-promising-data-on-adc-programs-including-early-clinical-results-of-rinatabart-sesutecan-in-ovarian-and-endometrial-cancers-at-sitc-2023

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #837

          Mon det ikke er tidligere medarbejdere i immunogen vi skal søge eller ?

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Raun
            wrote on sidst redigeret af
            #838

            Vi kan også sætte det hele på hovedet..... Det kostede 4% i reklamepenge.... Det har afstedkommet at markedet nu for alvor har fået øje på RinaS.... Så skal vi egentlig ikke bare takke Abbvie 😉

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #839

              Abbvies opfølger IMGN151 er i fase 1 siden december 2022 og har en DAR på 3,5 med deres payload DM21 https://aacrjournals.org/cancerres/article/80/16_Supplement/2890/642251/Abstract-2890-IMGN151-A-next-generation-folate Rina-S har DAR 6 med topoisomerase 1 inhibitor som payload. Hvilket stof der er bedst må tiden vise. Jeg har ikke fundet data på patienter fra IMGN151.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #840

                DAR of 8 I believe

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #841

                  Hej Raun. Jeg tænkte sjovt nok lidt det samme, da jeg læste meddelelsen

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #842

                    Correct DAR8 - Rina-S is an ADC comprised of a folate receptor-alpha-directed antibody conjugated to sesutecan, ProfoundBio’s novel, proprietary hydrophilic exatecan-based linker-drug, LD038, at a homogeneous drug-to-antibody ratio (DAR) of 8. Exatecan is a highly potent, membrane permeable topoisomerase-1 inhibitor with strong bystander effect that has been extensively studied as a small molecule anticancer agent. Sesutecan is a highly hydrophilic stable, cleavable linker designed to mask the

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #843

                      hydrophobicity of conjugated exatecan on the ADC, enabling high DAR and efficient delivery of the exatecan payload to tumors while maintaining favorable physicochemical and pharmacokinetic properties of the ADC.

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #844

                        Ifølge det tidligere link til omtalen af Abbvies sagsanlæg, så er det sådan, at "ProfoundBio began filing patents and promoting its linker technology in 2021," Så de kunne have anfægtet patentet i flere år

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #845

                          Den anklagede person er endda officiel medopfinder af ProfoundBios patent, så vedkommende har da ikke skjult sin relation til ProfoundBio, så igen: Abbvie har haft fere år, hvor de kunne have anfægtet patentet

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #846

                            Link Preview Image
                            US20240207429A1 - Linkers, drug linkers and conjugates thereof and methods of using the same - Google Patents

                            The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

                            favicon

                            (patents.google.com)

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #847

                              Rova-T: the story of AbbVie’s multi-billion dollar failure -I'll have another look at this story tomorrow, but maybe this is also about AbbVie having a grudge with former Stemcentrx employees... https://www.science.org/content/blog-post/last-stemcentrx

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #848

                                Everyone won big time on Stemcentrx except Abbvie. Is IMGN just another failure in the line af disasters by Abbvie ?

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #849

                                  Founder of Profound come from Stemcentrx got hired at Abbvie and left and then developed Rina-s which is better tha Elahere double whammy 😄

                                  1 Reply Last reply
                                  0
                                  • R Offline
                                    R Offline
                                    Raun
                                    wrote on sidst redigeret af
                                    #850

                                    😄

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #851

                                      What a story 🙂

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lahn1
                                        wrote on sidst redigeret af
                                        #852

                                        Abbvie tabte en meget ligende sag mod Adcentrx. Dommeren afviste sagen grundet manglende beviser på en kriminel handling. https://casetext.com/case/abbvie-inc-v-adcentrx-therapeutics-inc?utm_source=chatgpt.com&__cf_chl_rt_tk=6cLBbJCdxo3.l47PVnxvbN5nCD55gIk5u605i6EDfmg-1742847322-1.0.1.1-dnnmMeqSOFS.oHThbMIG.pnL8_CO9u_dEtkfHwXHyc8

                                        1 Reply Last reply
                                        0
                                        • T Offline
                                          T Offline
                                          transalp
                                          wrote on sidst redigeret af
                                          #853

                                          Go morgen.. 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper